Cyclosporine Vs Steroids in DRESS
Launched by UNIVERSITY OF SOUTHERN CALIFORNIA · Jul 31, 2021
Trial Information
Current as of July 05, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Current treatments for patients with drug reaction with eosinophilia and systemic symptoms (DRESS) include supportive care, steroids, cyclosporine and to a lesser extent, intravenous immunoglobulin (IVIG). Regarding IVIG, a recent case series suggests no improved benefit in adults. No randomized controlled trial (RCT) exists in comparing these treatments and all available literature comes in the form of case reports and case series. These two treatments are considered standard of care and this trial seeks only to compare outcomes of DRESS between these two therapies. No additional labs, the...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults with a RegiSCAR score of greater than 4 (i.e a likely diagnosis of DRESS)
- Exclusion Criteria:
- • Active sepsis
- • Active hepatitis B or C
- • Active tuberculosis
- • Documented allergy to steroids or cyclosporine
- • Estimated glomerular filtration rate (eGFR) \< 30 (unless on dialysis, in which case they will be included)
About University Of Southern California
The University of Southern California (USC) is a prestigious research institution located in Los Angeles, California, known for its commitment to advancing knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, USC leverages its extensive resources, interdisciplinary expertise, and state-of-the-art facilities to conduct cutting-edge research aimed at improving patient outcomes and public health. The university fosters collaboration among its diverse faculty and students, ensuring a dynamic environment for the development and implementation of clinical studies that adhere to the highest ethical and scientific standards. Through its clinical trials, USC aims to contribute to the advancement of medical science and the translation of research findings into practical applications that benefit communities locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials